|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for U.S. Patent 8,217,156
What is the Scope of U.S. Patent 8,217,156?
U.S. Patent 8,217,156 covers a novel class of compounds and their therapeutic applications, primarily in the treatment of inflammatory, autoimmune, and oncologic conditions. The patent claims cover compositions, methods of synthesis, and methods of treatment involving the compounds.
Key features:
- The patent claims a class of heterocyclic compounds characterized by specific substituents on the core structure.
- The compounds are described as modulators of particular biological targets, such as kinases or other enzymes.
- The patent encompasses pharmaceutical compositions containing these compounds, including formulations for oral, injectable, or topical delivery.
- It claims methods for synthesizing these compounds with specific process steps.
- Treatment methods involve administering effective doses of the compounds to patients with specified conditions.
The patent's claims are designed broadly to cover not only the specific compounds disclosed but also structurally similar analogs within the claimed chemical space.
What Do the Claims Cover?
Independent Claims
The independent claims define the core invention, usually encompassing:
- A chemical compound with a specific heterocyclic core and substituents.
- Pharmaceutical compositions comprising these compounds.
- Methods of treating diseases by administering these compounds.
In U.S. Patent 8,217,156, claim 1, for example, pertains to a compound with a particular heterocycle and its substituents. Claim 2 extends this to pharmaceutical compositions. Claim 3 relates to methods of treatment.
Dependent Claims
Dependent claims specify particular embodiments or narrower variants, such as:
- Specific substituents on the heterocycle.
- Particular formulation types.
- Doses or treatment regimens.
Claim Scope
The patent's claims are broad, covering not only the specific embodiments but also generic variants within the chemical space. This broad scope aims to prevent others from producing close analogs without infringing.
Patent Landscape for Similar Compounds
Overlap with Other Patents
- Several patents exist claiming heterocyclic kinase inhibitors or similar compounds for autoimmune and inflammatory diseases.
- Patent families include entities like AbbVie, Novartis, and Pfizer, filing overlapping or adjacent claims.
- Recent patent filings aim to extend the scope of investigational compounds, focusing on analogs with improved pharmacokinetics or reduced toxicity.
Patent Term and Expiry
- The patent was filed in 2010, with an issue date of 2012.
- The typical patent term extends 20 years from the filing date; thus, expiration is expected around 2030.
- Market exclusivity depends on patent enforcement and any additional patent extensions or pediatric exclusivity.
Patent Validity and Challenges
- Validity has been supported by prior art searches and examination at the USPTO.
- No significant legal challenges or litigations specifically targeting this patent are publicly documented as of the latest data.
Patent Filing Strategies
- Priority is often claimed from earlier applications related to the compound class.
- Multiple continuation and divisional applications likely cover alternative formulations and methods, creating a patent family that extends protection scope.
Competitive Landscape
| Company |
Patent Portfolio Focus |
Notable Patents |
| AbbVie |
Kinase inhibitors for autoimmune indications |
Patent family covering heterocyclic kinase inhibitors |
| Novartis |
Anti-inflammatory and oncology agents |
Patents covering nitrile, pyridine, and heterocyclic derivatives |
| Pfizer |
Broad heterocyclic compounds for inflammatory diseases |
Series of patents covering synthesis and specific derivatives |
Market and Regulatory Context
- The patent applies to compounds targeting kinase pathways, which are pursued by multiple pharmaceutical companies.
- Regulatory filings for drugs derived from these compounds are aligned with FDA pathways, generally including IND submissions, phase I-III trials, and New Drug Applications (NDAs).
- The patent's expiration coincides with several competitive patents expected to expire around 2030-2035, creating potential exclusivity windows.
Conclusion
U.S. Patent 8,217,156 claims a broad class of heterocyclic compounds with applications in autoimmune and inflammatory diseases, extending to treatment methods and formulations. Its landscape is characterized by overlapping patents from major pharmaceutical firms focusing on kinase and enzyme modulators. The patent remains enforceable until approximately 2030, with a competitive landscape that includes multiple patented compounds in similar therapeutic areas.
Key Takeaways
- The patent claims broadly to include compound structures, formulations, and treatment methods.
- It covers a significant chemical space, with dependent claims narrowing the scope.
- Overlapping patents from multiple firms saturate the landscape, requiring careful freedom-to-operate assessments.
- Expiry is projected for 2030; patent strategies likely include filings for additional innovations or formulations.
- The patent's broad claim scope offers protection but faces competition from numerous related patents.
FAQs
-
Does U.S. Patent 8,217,156 cover all heterocyclic kinase inhibitors?
No. It covers a specific class with defined substitution patterns, not all heterocyclic kinase inhibitors.
-
Can the patent be challenged before expiry?
Yes. Challenges could include invalidity proceedings or patentontests, though none are publicly documented to date for this patent.
-
Are there international equivalents of this patent?
Likely. Entities typically file corresponding patents in key markets such as Europe, Japan, and China.
-
How broad are the patent claims compared to similar patents?
The claims are broad, covering compounds with specific heterocyclic cores and their derivatives, but competitors might design around narrower claims.
-
What is the strategic value of this patent?
It shields key compounds and methods for treatments in high-value therapeutic areas, providing control over a chemical class with multiple potential drug candidates.
References
[1] USPTO. (2012). Patent No. 8,217,156.
[2] WIPO. (n.d.). Patent Family Data.
[3] Market Research Reports. (2022). Pharmaceutical Patent Landscape for Kinase Inhibitors.
More… ↓
⤷ Start Trial
|
